HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gillette

This article was originally published in The Rose Sheet

Executive Summary

Global launch of prescription drug hair removal cream Vaniqa (eflornithine 15%) to be handled by Chicago-based DDB Corbett, a joint venture between Frank J. Corbett, Inc. and DDB Chicago. The firm will handle all professional communications, direct-to-consumer advertising and Web site development of the drug product. The Vaniqa launch will begin in the U.S. and roll out to four additional countries. Gillette and Bristol-Myers Squibb filed the Vaniqa NDA Sept. 27 (1"The Rose Sheet" Oct. 11, 1999, p. 12). Under the agreement, BMS is handling the FDA submissions and clinical development and will market the prescription product in partnership with Gillette
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS007626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel